CMVpp65/gB Plasmid Vaccine ASP0113

Known as: ASP0113, TransVax 
A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2017
0120122017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Cytomegalovirus (CMV) is a latent infection in most infected individuals, but can be pathogenic in immunocompromised kidney… (More)
Is this relevant?
2017
2017
Cytomegalovirus (CMV) infection/reactivation is a serious complication after hematopoietic cell transplantation (HCT). The DNA… (More)
Is this relevant?
Review
2015
Review
2015
Passive immunization against CMV is desirable to minimize or perhaps eliminate complications related to CMV disease. In… (More)
Is this relevant?
Review
2014
Review
2014
Cytomegalovirus (CMV) is one of the most significant viral pathogens during pregnancy and in immunocompromised patients… (More)
Is this relevant?
2013
2013
 
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Cytomegalovirus reactivation occurs within 6 months in 60-70% of cytomegalovirus-seropositive patients after… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?